Rituximab May Have Advantages Over Fingolimod and Natalizumab in MSDecember 28, 2016Multiple Sclerosis
Lack of natalizumab concentration increase before PML argues against extending dosing intervalDecember 14, 2016Multiple Sclerosis
Nomogram predicts conversion of first demyelinating event to definite MSDecember 5, 2016Multiple Sclerosis